GlioME: Gliomagenèse et MicroEnvironment

The GlioME Team has new publication out in International Journal of Molecular Sciences as part of the Special Issue « Emerging Therapies for Glioblastoma ». This article deals with one of the team’s key issues, the gangliosides recognized by the A2B5 antibody and used as biomarker of cancer stem cells (CSC) in glioblastoma human brain tumours.

Membre expert du comité éditorial et co-auteur de plusieurs chapitres de la 5ème édition de la Classification des tumeurs du SNC de l’OMS parue le 12 novembre dernier, Dominique Figarella-Branger (Equipe 8 GlioME) a dirigé la rédaction d'un article de revue en français sur cette nouvelle classification, récemment publié dans les Annales de Pathologie: https://authors.elsevier.com/c/1eB1VtB1GOhjB

The cIMPACT-NOW Working Committee is the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. cIMPACT-NOW  was created in late 2016 —following publication of the 2016 Updated 4th Edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System— to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications.

We obtained results showing the crucial role of the A2B5 epitope in the promotion of proliferation, migration, clonogenicity, and tumorigenesis of glioblastoma cells, indicating that the glycolipids recognized by the A2B5 antibody are attractive targets for glioblastoma therapy.

Our last work on IAPs : "Inhibitor of Apoptosis Proteins (IAPs) Determines Glioblastoma Stem‐Like Cell Fate in an Oxygen‐Dependent Manner" is now published in Stem Cells. We highlighted that pharmacological inhibition of IAPs by Smac mimetic GDC-0152 was able to decrease glioblastoma stem-like cells viability in hypoxia by decreasing cell proliferation and increasing apoptosis through ATR and TNFα pathways